Laserscope Comments On Appointment of
New CEO
SAN JOSE, Calif.--(BW HealthWire)--June 22, 1999--Laserscope (Nasdaq:LSCP - news) today provided additional details
about the recent appointment of Eric Reuter as President and CEO.
According to Robert J. Pressley, Laserscope Chairman: ''The Board's appointment of Eric Reuter as President and CEO
represents a refocusing of Laserscope's priorities to more effectively capitalize on the Company's outstanding technology
base. With Eric at the helm, we have a professional manager with a high level of energy and enthusiasm in a position of
corporate leadership who fully understands how to leverage Laserscope's strengths.''
Reuter, 38, joined Laserscope in September 1996 as Vice President of Research and Development. Before joining
Laserscope, Reuter had engineering management responsibility for the design and construction of the B-meson factory
high-energy electron storage ring of the Stanford Linear Accelerator Center at Stanford University. Earlier, he was a senior
mechanical engineer and program manager with the Oncology Care Division of Siemens Medical Systems. He holds
bachelor of science degrees in mechanical engineering and materials science from the University of California at Davis. He
also completed the Stanford Executive Program in Product Development and Manufacturing Strategy.
Added Pressley: ''As Vice President of Research and Development for the past two and a half years, Eric Reuter led the
commercial development of both the Venus and Hair Removal Laser Systems, and initiated research into some very
innovative areas that will form the basis of future product lines. He also managed both the clinical and regulatory affairs
functions, two activities which form the basis of successful product development and marketing programs. Additionally, by
building new products on common platforms and subsystems, he is making strong inroads into reducing manufacturing
costs and improving gross margins. Eric's ambition, intelligence and passion will make him an outstanding leader and chief
executive at Laserscope.''
Laserscope designs, manufactures, sells, and services on a worldwide basis an advanced line of medical laser systems and
related energy delivery devices for the office, outpatient surgical center, and hospital markets. The Company is a pioneer in
the development of lasers and fiber-optic devices for photodynamic therapy to treat cancer and other diseases. More
information on Laserscope can be found on the company's Web site at www.laserscope.com or
www.photodynamictherapy.com.
Any statements in this announcement about future results are preliminary and based on partial information and assumptions,
and actual results may differ. Except for historical information presented, the matters discussed in this announcement contain
forward-looking statements that involve risks and uncertainties. These risks and uncertainties are detailed from time to time
in the company's public disclosure filings with the U.S. Securities and Exchange Commission (SEC). Copies of
Laserscope's most recent forms 10K and 10Q are available upon request from its Investor Relations Department.
Contact:
Laserscope
Richard Wood, 408/943-0636 (IR/Media)
Dennis LaLumandiere, 408/943-0636 (Financial)
or
PR Agency Contacts:
Hilary Kaye Associates
Joan Murray or Hilary Kaye, 714/426-0444
or
IR Agency Contacts:
FIN-COM
Larry Selwitz, 562/493-2770
Eugene Anton, 714/426-0228 |
